Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Bifidobacterium breve BBG-01 in preterm infants to prevent infection, necrotising enterocolitis and death
2006-003445-17Phase 3Completed
- Sponsor
- Queen Mary University of London
- Start
- Apr 2009
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Bifidobacterium breve BBG-01 in necrotizing enterocolitis (NEC), bloodstream infection (BSI), sepsis and 1 more, sponsored by Queen Mary University of London. Primary endpoint: Primary: late-onset bloodstream infection, death or discharge. Started Apr 2009; status: completed.
02
Drugs
Bifidobacterium breve BBG-01
03
Conditions
necrotizing enterocolitis (NEC)bloodstream infection (BSI)sepsismortality
Beyond the preview
Go deeper on 2006-003445-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003445-17.